Heart / Stroke-RelatedWomen's ProblemsCardiologyFamily PracticeNeurologyOBGYN & Women's HealthInternal MedicineCritical CareCardiovascular DiseasesHeart HealthWomen HealthWomen'S HealthPublic HealthClinical Trials
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
THURSDAY, Feb. 27, 2020 (HealthDay News) -- Men still dominate participation in cardiovascular clinical trials, according to a study published online Feb. 17 in Circulation.
Xurui Jin, M.D., from Duke Kunshan University in Suzhou, China, and colleagues systematically assessed the participation of women in completed cardiovascular trials registered in ClinicalTrials.gov between 2010 and 2017. The female-to-male ratio was calculated for each trial.
The researchers identified 740 completed cardiovascular trials that included 862,652 adults (38.2 percent women). The median female-to-male ratio of each trial was 0.51 with variance by age group (1.02 in ≤55 years old versus 0.40 in 61- to 65-year-olds). Differences in the female-to-male ratio were also seen by type of intervention (0.44 for procedural trials versus 0.78 for lifestyle intervention trials), disease type (0.34 for acute coronary syndrome versus 3.20 for pulmonary hypertension), region (0.45 for Western Pacific versus 0.55 for the Americas), funding/sponsor type (0.14 for government-funded versus 0.73 for multiple sponsors), and trial size (0.56 for smaller versus 0.49 for larger trials). Compared with previous periods, there were significant increases in participation prevalence ratios for stroke and heart failure trials in 2013 to 2017.
"Future efforts should build on previous successes and target key areas for improvement with multifactorial approaches to enhance recruitment of women," the authors write.
One author disclosed financial ties to the pharmaceutical industry.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on May 26, 2022
Read this Next
Other Trending Articles